SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves steep selloff and repeated tests of its yearly lows are drawing attention amid concerns about heavy debt, costly financing, refinancing needs and insider selling, alongside broader doubts about AI-infrastructure spending. Traders are split: bears see financing risks as a threat to growth, while bulls point to its backlog and AI partnerships and view the selloff as overdone; analyst upgrades and ARKs buying have not dispelled skepticism.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is drawing attention amid a semiconductor selloff, with traders focused on CEO Hock Tans warning that some AI investing resembles gambling and his comments about capital constraints. The remarks and worries about AI spending and financing have fueled bearish sentiment, while other traders see the pullback as a buying opportunity based on Broadcoms AI-chip growth; many also complain that the stock has lagged semiconductor peers.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras is drawing attention as its steep post-IPO selloff continues, with traders citing upcoming share unlocks, reported insider sales, a TD Cowen downgrade and concerns about OpenAI customer concentration and competition from Nvidia. Others argue the decline is overdone, pointing to Cerebras AI-chip technology and potential demand, while broader weakness in AI and semiconductor stocks adds pressure.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is drawing attention amid a steep selloff and worries that its debt-funded AI data-center expansion, heavy capital spending, and weak free cash flow may be difficult to finance as credit costs rise and inflation fuels rate concerns. Bears question whether its backlog and AI demand will translate into cash flow, while bulls argue Oracles cloud business and contracted demand make the pullback an opportunity.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is rebounding alongside semiconductor stocks after a steep, extended selloff, drawing dip buyers who see oversold conditions and continued AI-chip demand as support for a recovery. Others warn the bounce may be temporary, citing concerns about AI investment returns and debt, market uncertainty, and upcoming chip-sector earnings.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is drawing attention amid a sharp AI/neocloud selloff fueled by concerns about financing, debt exposure and whether infrastructure spending will earn adequate returns. Traders are divided over whether the rebound is an oversold relief move or a pause before further declines, with some arguing Nebius is better positioned than more leveraged peers.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is drawing attention amid a pullback and tentative rebound in AI and semiconductor stocks, as traders debate whether data-center spending can generate adequate returns and whether financing stress at firms such as CoreWeave signals broader risk. Bulls point to sustained chip demand and upcoming company updates, while bears remain concerned about AI valuations, debt exposure, and competition.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celesticas large equity offering has pressured shares, with traders citing dilution even as the capital is intended to support expansion. The selloff is being debated against the bullish AI and data-center demand outlook, prompting dip-buying while others remain concerned about volatility and the stocks valuation.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech and semiconductor rebound after the AI-related selloff has lifted QQQ, with traders debating whether it marks a durable recovery or a short-lived relief bounce. Upcoming megacap earnings and concerns about AI spending, oil prices, and inflation are keeping sentiment divided.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

JPMorgans upgrade of Intel to Neutral from Underweight, citing improving execution, is a key focus after a sharp selloff. Some traders see it as validation of the turnaround, while others dismiss the upgrade because the price target was unchanged; broader chip-sector weakness and unconfirmed foundry-deal speculation add to the debate.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has been selected to deliver a late-breaking oral presentation at The...

Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the dosing of the first patient in August in the Phase 1/2 FUNCTION-DMD clinical...

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the second quarter ended June 30, 2026, and provided a...

Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will publish financial results for the second quarter 2026 and provide a...

Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced changes to its senior leadership team. Alex Kelly, currently Chief Financial...

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that, on July 5, 2026, the Compensation Committee of Precisions Board of Directors...

Strength Seen in Precision BioSciences (DTIL): Can Its 12.3% Jump Turn into More Strength?

Precision BioSciences (DTIL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Precision BioSciences Announces Inclusion in the Russell 2000 Index Expanding Market Visibility with Institutional Investors

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced its addition to the Russell 2000 Index, effective at the close of U.S. equity...

Why Is Precision BioSciences Stock Gaining Wednesday?

Precision BioSciences (DTIL) trades up 10.55% premarket. Bullish moving averages and new data point to strong momentum.read more...

Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the presentation of new and late-breaking clinical data from the ELIMINATE-B study...

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Precision Biosciences Inc

Precision Bio's DMD Therapy Gets Rare Pediatric Status, But Stock Slides; Retail Crowd Sees ‘Good Risk-Reward’

Equity

Bearish Sentiment

Precision BioSciences drew heightened retail investor chatter on Wednesday after the FDA awarded Rare Pediatric Disease designation to its gene editing therapy PBGENE-DMD, which targets duchenne muscular dystrophy (DMD) treatment.The stock surged as much as 9% during regular trading but reversed course to close down 7.2% at $4.24, and extended losses in after-hours trading, slipping 3.5%.The designation, which is intended to provide incentives for the development of drugs and biologics for serious and life-threatening conditions that predominantly affect individuals under age 18, could provide Precision with a priority review voucher (PRV) upon approval of the drug.PRVs can be redeemed for accelerated FDA review of a different drug or sold to other companies, creating potential for non-dilutive capital.Precision’s chief development and business officer, Cindy Atwell, said the designation supports the potential of PBGENE-DMD to deliver a “meaningful improvement and durable functional benefit” for up to 60% of patients.PBGENE-DMD is a first-in-class in vivo gene editing therapy that uses the company’s proprietary Arcus platform, designed to excise exons 45–55 of the dystrophin gene using two Arcus nucleases delivered in a single Adeno-associated virus (AAV).&nbsp;The one-time treatment aims to restore a near full-length, naturally produced dystrophin protein, considered functional in humans.In preclinical studies, PBGENE-DMD showed:<ul class="todo-list"><li><label class="todo-list__label"><input type="checkbox" disabled="disabled">Significant, durable functional improvements in a humanized DMD mouse model</label></li><li><label class="todo-list__label"><input type="checkbox" disabled="disabled">Restoration of dystrophin production in key muscle types, including cardiac and skeletal muscle</label></li><li><label class="todo-list__label"><input type="checkbox" disabled="disabled">Editing of satellite muscle stem cells, believed to be important for long-term durability</label></li></ul>&nbsp;The company is currently completing final IND-enabling toxicology studies and said it expects to begin clinical testing in 2026.Precision also said that its Arcus platform enables precise, defined therapeutic gene edits using a small, structurally distinct nuclease, supporting gene insertion, elimination, and excision.&nbsp;On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 4,025% surge in 24-hour message volume.One user pointed to Precision’s cash reserves of over $80 million and described the current setup as a “good risk-reward,” suggesting the downside appears limited while the potential upside could be unlimited.<stembedurl>https://stocktwits.com/pinkal/message/619015289</stembedurl>Another user, reflecting on a much higher cost basis from early 2021, assessed whether the current dip might offer a fresh buying opportunity.<stembedurl>https://stocktwits.com/foxhedgehog/message/618993420</stembedurl>The stock has declined 9.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The FDA designation could make Precision eligible for a valuable Priority Review Voucher, while preclinical data showed strong dystrophin restoration across key muscle groups.

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Stocktwits

SpaceX

Netflix Inc

Meta Platforms Inc

Which earnings release are you most looking forward to this week: 

Stocktwits Polls

More positive news today from $DTIL partner Imugene on their P1b Azer-Cell trial. Another complete response and one partial response. Immugene is gonna need to find a partner or flip this back to Precision but great news. Overall Response Rate now at 71%.

hey_jakey

$DTIL — Precision BioSciences is taking gene editing in a different direction with its ARCUS platform.

Rather than being another CRISPR company, ARCUS uses a distinct type of programmable nuclease designed for precise DNA editing.

DTIL is presenting at this week’s cell and gene-therapy conference, and I’m watching for updates on clinical development and partnerships.

Different editing technology + a small valuation makes this an interesting speculative biotech to research.

Trading Edge

Press Release from 10/8: 
​Michael S. Weiss, Chairman and Chief Executive Officer of TG Therapeutics @TGTX, stated, “We are extremely pleased that the first clinical results from our azer-cel program in progressive multiple sclerosis have been selected for a late-breaking oral presentation at MSToronto2026.$DTIL

$DTIL Expecting additional biopsy data, hopefully from the higher dose cohort, but even the low dose was pretty spectacular.

$DTIL The AASLD The Liver Meeting 2026 will take place from Thursday, November 5, to Monday, November 9, 2026, at the Colorado Convention Center in Denver, Colorado

Redoak

$DTIL If azer-cel data are exceptional, why wouldn’t TG consider acquiring Precision outright? DTIL’s market cap is a fraction of the ~$286M in potential milestone payments, and that doesn’t even include future royalties.

Bryan Fodness

$DTIL  First Clinical Evaluation of an Allogeneic CD19-Directed CAR T-Cell Therapy in Progressive Multiple Sclerosis: Initial Results From the Phase 1 TG-Azercel-101 Study 

MS Toronto 2026 Oct 23

Feed

News

Sentiment

Earnings

Fundamentals

Info

DTIL Precision Biosciences Inc

Fundamentals

Latest DTIL News